In a trial of daraxonrasib, a pill for advanced pancreatic cancer, tumours stopped growing in 90% of the 61 participants, while scans showed the cancer had become undetectable in about 8%. Researchers say longer studies are needed to establish how long the effects last and whether the drug can put the cancer into remission.
The participants had recently been diagnosed with pancreatic cancer that had spread to other parts of the body. During an average follow-up of 18 months, just over 60% saw their tumours shrink or disappear. Some patients had no return of the cancer during that period.
A year after starting treatment, 76.6% of participants were alive. The article says 40-45% of patients given chemotherapy alone usually survive for a year.
Doctors cautioned that daraxonrasib cannot yet be considered a cure, and its effect on the disease’s duration is not known. They said the findings are encouraging because the treatment may give patients more time, even without full remission.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. He said “this is the closest to cure”, adding that he had never seen so many tumours disappear in patients whose cancer had spread.
“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” Park said. He added: “The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”
Daraxonrasib is a KRAS inhibitor that works by locking on to and shutting off certain mutations found in most pancreatic cancers. These mutations drive tumour growth. The treatment may also work for other cancers with similar mutations, according to the article.
Michelle Mitchell, Cancer Research UK’s chief executive, said more research was needed. “This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers,” she said.
Mitchell said the findings raise the possibility that the treatment could eventually be used against other cancers carrying Kras gene mutations. “More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low,” she said.
The article says half of all people diagnosed with pancreatic cancer die within three months. When the disease has spread to other organs, about 3% of patients survive for five years; pancreatic cancer has the lowest survival rate of all common cancers in the UK.
